Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis, which offers opportunities to access and influence brain centers involved in fundamental human processes.
Kallyope, Inc.
Management
Technology
Deals/Partnering
Research Pipeline
Funding
BioStartup's Score
0 / 50
KEY DETAILS
Websitehttps://www.kallyope.com
Disease Focus
STOCK CODENon Listed
Address430 East 29th Street, 10th Floor, NY 10016New YorkUnited States
430 East 29th Street, 10th Floor, NY 10016
New York
United States
Contact Number
Kallyope is a platform biotechnology company dedicated to unlocking the therapeutic and nutritional product potential of the gut-brain axis, which offers opportunities to access and influence brain centers involved in fundamental human processes.
The companys founders are Charles Zuker, Ph.D., Lasker Award winner Tom Maniatis, Ph.D. and Nobel laureate Richard Axel, M.D. Headquartered at the Alexandria Centerë for Life Science in New York City.
[atom_linkedin linkedin_option=”CompanyInsider” linkedin_id=”https://www.linkedin.com/company/kallyope” connections=”true” suffix=””]
In Feb 2018, Kallyope Inc received $66 million Series B financing investors participated in the Series B, including Lux Capital, The Column Group, Polaris Partners, Illumina Ventures, and Alexandria Venture Investments. New investors Euclidean Capital and Two Sigma Ventures also joined the syndicate.
In Dec 2015, Kallyope raised $44 Mn in Series A financing round. Key investors includes Lux Capital, Polaris Partners, Alexandria Venture Investments, The Column Group and Illumina.